Action and use<\/strong><\/p>\n Glucocorticoid.<\/p>\n Preparations<\/strong><\/p>\n Fluocinolone Cream<\/p>\n Fluocinolone Ointment<\/p>\n 6\u03b1,9-Difluoro-11\u03b2,21-dihydroxy-16\u03b1,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione.<\/p>\n 97.5 per cent to 102.0 per cent (dried substance).<\/p>\n White or almost white, crystalline powder.<\/p>\n Practically insoluble in water, soluble in acetone and in anhydrous ethanol, practically insoluble in heptane.<\/p>\n It shows polymorphism (5.9).<\/p>\n A. Infrared absorption spectrophotometry (2.2.24).<\/p>\n Comparison fluocinolone acetonide CRS.<\/p>\n If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in anhydrous ethanol R, evaporate to dryness and record new spectra using the residues.<\/p>\n B. Examine the chromatograms obtained in the assay.<\/p>\n Results: The principal peak in the chromatogram obtained with test solution (b) is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (d).<\/p>\n + 100 to + 104 (dried substance).<\/p>\n Dissolve 0.100 g in anhydrous ethanol R and dilute to 10.0 mL with the same solvent.<\/p>\n Liquid chromatography (2.2.29). Carry out the test protected from lightand prepare the solutions immediately before use.<\/p>\n Solvent mixture acetonitrile R, water R (20:80 V\/V).<\/p>\n Buffer solution: Dissolve 5.68 g of anhydrous disodium hydrogen phosphate R and 3.63 g of potassium dihydrogen phosphate R in water R and dilute to 1000.0 mL with the same solvent.<\/p>\n Test solution (a): Dissolve 20.0 mg of the substance to be examined in 20 mL of acetonitrile R and dilute to 100.0 mL with water R.<\/p>\n Test solution (b): Dilute 1.0 mL of test solution (a) to 10.0 mL with the solvent mixture.<\/p>\n Reference solution (a): Dissolve 2 mg of fluocinolone acetonide for system suitability CRS (containing impurities H, J and K) in 2 mL of acetonitrile R and dilute to 10.0 mL with water R.<\/p>\n Reference solution (b): Dissolve 2 mg of fluocinolone acetonide for peak identification CRS (containing impurities D and I) in 2 mL of acetonitrile R and dilute to 10.0 mL with water R.<\/p>\n Reference solution (c): Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.<\/p>\n Reference solution (d): Dissolve 20.0 mg of fluocinolone acetonide CRS in 20 mL of acetonitrile R and dilute to 100.0 mL with water R. Dilute 1.0 mL of the solution to 10.0 mL with the solvent mixture.<\/p>\n Column:<\/p>\n \u2014 size: l = 0.25 m, \u00d8 = 4.6 mm;<\/p>\n \u2014 stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 \u03bcm).<\/p>\n Mobile phase:<\/p>\n \u2014 mobile phase A: acetonitrile R, buffer solution (28:72 V\/V);<\/p>\n \u2014 mobile phase B: water R, acetonitrile R (40:60 V\/V);<\/p>\n (min)<\/td>\n (per cent V\/V)<\/td>\n (per cent V\/V)<\/td>\n<\/tr>\n Flow rate: 1.0 mL\/min.<\/p>\n Detection: Spectrophotometer at 238 nm.<\/p>\n Injection: 40 \u03bcL of test solution (a) and reference solutions (a), (b) and (c).<\/p>\n Identification of impurities: Use the chromatogram supplied with fluocinolone acetonide for system suitability CRS and the chromatogram obtained with reference solution (a) to identify the peaks due to impurities H, J and K; use the chromatogram supplied with fluocinolone acetonide for peak identification CRS and the chromatogram obtained with Relative retention: With reference to fluocinolone acetonide (retention time = about 18 min): impurity D = about 0.8; impurity H = about 0.90; impurity I = about 0.94; impurity J = about 1.05; impurity K = about 1.2.<\/p>\n System suitability: Reference solution (a):<\/p>\n \u2014 peak-to-valley ratio: minimum 5.0, where Hp = height above the baseline of the peak due to impurity J and Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to fluocinolone acetonide.<\/p>\n Calculation of percentage contents:<\/p>\n \u2014 correction factor: multiply the peak area of impurity K by 1.3;<\/p>\n \u2014 for each impurity, use the concentration of fluocinolone acetonide in reference solution (c).<\/p>\n Limits:<\/p>\n \u2014 impurity K: maximum 0.3 per cent;<\/p>\n \u2014 impurities D, J: for each impurity, maximum 0.2 per cent;<\/p>\n \u2014 impurities H, I: for each impurity, maximum 0.15 per cent;<\/p>\n \u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n \u2014 total: maximum 0.7 per cent;<\/p>\n \u2014 reporting threshold: 0.05 per cent.<\/p>\n Maximum 1.0 per cent, determined on 1.000 g by drying in an oven at 105 \u00b0C for 3 h.<\/p>\n Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.<\/p>\n Injection: 20 \u03bcL of test solution (b) and reference solution (d).<\/p>\n Calculate the percentage content of C24<\/sub>H30<\/sub>F2<\/sub>O6<\/sub> taking into account the assigned content of fluocinolone acetonide CRS.<\/p>\n Protected from light.<\/p>\n Specified impurities D, H, I, J, K.<\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A, B, C, E, F, G, L, M.<\/p>\n A. 6\u03b1,9-difluoro-11\u03b2-hydroxy-16\u03b1,17-(1-methylethylidenedioxy)-3,20-dioxopregna-1,4-dien-21-oic acid,<\/p>\n B. 6\u03b1,9-difluoro-11\u03b2-hydroxy-16\u03b1,17-(1-methylethylidenedioxy)-3-oxoandrosta-1,4-diene-17\u03b2-carboxylic acid,<\/p>\n C. 6\u03b1,9-difluoro-11\u03b2,16\u03b1,17,21-tetrahydroxypregna-1,4-diene-3,20-dione (fluocinolone),<\/p>\n D. 6\u03b1,9-difluoro-11\u03b2-hydroxy-16\u03b1,17-(1-methylethylidenedioxy)-3,20-dioxopregna-1,4-dien-21-al,<\/p>\n E. 9,11\u03b2-epoxy-6\u03b1-fluoro-21-hydroxy-16\u03b1,17-(1-methylethylidenedioxy)-9\u03b2-pregna-1,4-diene-3,20-dione,<\/p>\n F. 6\u03b1-fluoro-21-hydroxy-16\u03b1,17-(1-methylethylidenedioxy)pregn-4-ene-3,20-dione,<\/p>\n G. 6\u03b1-fluoro-11\u03b2-hydroxy-16\u03b1,17-(1-methylethylidenedioxy)-3,20-dioxopregn-4-en-21-yl acetate,<\/p>\n H. 9-fluoro-11\u03b2,21-dihydroxy-16\u03b1,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione,<\/p>\n I. 6\u03b1,9-difluoro-11\u03b2,21-dihydroxy-16\u03b1,17-(1-methylethylidenedioxy)pregna-1,4,14-triene-3,20-dione,<\/p>\n J. 6\u03b2,9-difluoro-11\u03b2,21-dihydroxy-16\u03b1,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione,<\/p>\n K. 4,9-difluoro-11\u03b2,21-dihydroxy-16\u03b1,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione,<\/p>\n L. 6\u03b1-chloro-9-fluoro-11\u03b2,21-dihydroxy-16\u03b1,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione,<\/p>\n M. 6\u03b1,9-difluoro-11\u03b2-hydroxy-16\u03b1,17-(1-methylethylidenedioxy)-3,20-dioxopregna-1,4-dien-21-yl acetate.<\/p>\n","protected":false},"excerpt":{"rendered":" (Ph. Eur. monograph 0494) C24H30F2O6 452.5 67-73-2 Action and use Glucocorticoid. Preparations Fluocinolone Cream Fluocinolone Ointment DEFINITION 6\u03b1,9-Difluoro-11\u03b2,21-dihydroxy-16\u03b1,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione. Content 97.5 per cent to 102.0 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Practically insoluble in water, soluble in acetone and in anhydrous ethanol, practically insoluble in heptane. It shows polymorphism…<\/p>\n","protected":false},"author":4,"featured_media":14926,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-14908","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/14908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=14908"}],"version-history":[{"count":4,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/14908\/revisions"}],"predecessor-version":[{"id":14970,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/14908\/revisions\/14970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/14926"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=14908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=14908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=14908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
Content<\/h3>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
Solubility<\/h3>\n
IDENTIFICATION<\/h2>\n
TESTS<\/h2>\n
Specific optical rotation (2.2.7)<\/h3>\n
Related substances<\/h3>\n
\n\n
\n Time<\/p>\n Mobile phase A<\/p>\n Mobile phase B<\/p>\n \n 0 – 2<\/td>\n 100<\/td>\n 0<\/td>\n<\/tr>\n \n 2 – 42<\/td>\n 100 \u2192 0<\/td>\n 0 \u2192 100<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\nreference solution (b) to identify the peaks due to impurities D and I.<\/p>\nLoss on drying (2.2.32)<\/h3>\n
ASSAY<\/h2>\n
STORAGE<\/h2>\n
IMPURITIES<\/h2>\n
![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-206-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-193-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-175-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-141-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-92-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-110-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-68-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/10-41-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Fluocinolone-Acetonide-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/11-28-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/11-27-300x163.jpg\")
<\/p>\n![\"Fluocinolone](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/13-17-300x163.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/12-19-300x163.jpg\")
<\/p>\n